Background: This randomized, double-blind trial was conducted to determine the
| INTRODUCTION
In Europe and North America, exposure to pollen from birch and other related trees may lead to development of respiratory allergic diseases such as allergic rhinoconjunctivitis (ARC). The prevalence of birch pollen sensitization in adults has been estimated to be more than 20% in some areas of central Europe, with a mean prevalence of 8% of the population in 13 developed countries worldwide. 1 Based on amino acid sequence homology of the major allergens and IgE cross-reactivity, five tree species (birch, alder, hornbeam, hazel, and oak) have been assigned to the same homologous group 2 termed the "birch homologous group", with birch as the representative species. An additional two species (beech and chestnut) have been suggested as members of the birch homologous group. 3 The relevance of birch pollen as a representative allergen source has been confirmed by in vitro IgE inhibition studies in which birch pollen extract almost completely inhibited human IgE binding to alder, hazel, hornbeam, and oak allergen extracts. 4 Patients who are allergic to birch pollen may also experience symptoms in response to pollen from the other members of the birch group, which, due to successive seasons and geographical distribution of the birch group species, increases the burden of tree pollen allergy in terms of relevant seasons and regions. 5 The SQ tree SLIT-tablet is being developed as allergy immunotherapy (AIT) for treatment of ARC induced by pollen from the birch group. Data from a phase I trial suggested that doses up to 12 development units (DU) have a tolerability profile suitable for athome administration. 6 Efficacy of the SQ tree SLIT-tablet (in doses from 0.5 to 12 DU) was evaluated in a phase II trial (EudraCT 2012-000031-59) which was a randomized, double-blind, placebo-controlled trial in 637 adults and adolescents with moderate to severe ARC induced by birch. 7 The tree pollen season, in which the phase II trial was conducted, was short and characterized by low birch pollen counts. 8 Consequently, the trial did not show a dose response for the primary endpoint (daily symptom score during the birch pollen season). However, clinical data and IgG 4 measurements suggested that the optimal dose for clinical efficacy was above 4 DU.
The present trial was conducted to confirm the optimal dose for clinical efficacy using an environmental exposure chamber (EEC) to eliminate variability of allergen exposure in different trial sites or seasons. [9] [10] [11] While in the EEC, birch allergic subjects are expected to experience rhinoconjunctivitis symptoms similar to what is normally experienced during the BPS. 12 To investigate the clinical efficacy of the SQ tree SLIT-tablet towards other species from the birch homologous group, subjects were exposed to white oak pollen (Quercus alba;
Que a) in separate EEC sessions. Immunological analyses (specific IgE, IgG 4 , and IgE-blocking factor (IgE-BF)) were performed throughout the treatment period in order to characterize sensitization profiles and the ability of the SQ tree SLIT-tablet to induce immunological responses that cover all species in the birch homologous group.
| METHODS

| Ethics
The trial is identified by ClinicalTrials.gov Identifier NCT02481856. The trial was designed and conducted in accordance with the principles of
G R A P H I C A L A B S T R A C T
Treatment with the SQ tree SLIT-tablet, induced statistically significant reductions of rhinoconjunctivitis symptoms compared to placebo, in birch allergic subjects exposed to birch or oak pollen in an environmental exposure chamber. Statistically significant differences between 12 DU and placebo were reached after 16 weeks treatment and persisted until week 24 (end-of-trial). The reduction in rhinoconjunctivitis symptoms during oak pollen exposure, provides proof of concept for clinically relevant therapeutic cross-reactivity between birch and other trees in the birch homologous group, which was also supported by IgG 4 measurements. *P<0.05; SLIT: sublingual allergy immunotherapy tablet; SQ:
SQ is a method of standardisation; DU: development unit.
the Declaration of Helsinki and its amendments 13 and conducted in compliance with the principles of ICH Good Clinical Practice. 
| Trial design
The trial was a phase II, randomized, parallel-group, double-blind, pla- 
| Trial population
The subjects eligible for the trial were adults (18- 
| Interventional medicinal product
The IMP was an oral lyophilisate (fast dissolving, freeze-dried formulation) for sublingual administration provided by ALK (Hoersholm, Denmark). The drug substance used for the active doses (2, 7, and 12 DU) was an allergen extract derived from birch pollen. DU has been used as a standardized potency unit during the development programme and is based equally on the major allergen content (Bet v 1) and total allergenic activity. One DU corresponds to approximately 5 μg Bet v 1. The matrix used was identical to the other SQ SLIT-tablets (eg. grass, house dust mite, and ragweed). The placebo tablets were similar to the active IMP with regard to appearance, smell, and taste. The first dose was administered under medical supervision lasting at least 30 minutes after tablet intake. Subjects were instructed to take one sublingual tablet daily. Before the subjects attended each of the EEC sessions, a washout period ranging from 3 days (short acting antihistamines and nasal decongestants) to 120 days (eg. for glucocorticoids and, systemic depot formulations) was specified for relevant concomitant medication that interfered with the efficacy evaluations. If deemed necessary by the investigator, subjects could be provided with antihistamines or a β2-agonist inhaler after an EEC session. None of the patients needed oral corticosteroids after the EEC sessions.
| Allergen exposure
During the EEC sessions, subjects were exposed to airborne birch pollen at a density of 3500 ± 500 grains/m 3 or to oak pollen in a density of 2000 ± 500 grains/m 3 for six consecutive hours. The pollen levels used in the birch EEC sessions resembled what could be experienced during the peak season under natural exposure. 8 Pollen counts were obtained using rotational impaction samplers every 30 minutes during the EEC sessions to ensure stable pollen exposure.
| Randomization
Each subject was randomly assigned to receive one of three active doses (2, 7, or 12 DU) or placebo. Randomization was performed according to an allocation schedule generated by a trial-independent statistician and was stratified by sites using block randomization.
Details on the randomization can be found in the Appendix S1. 
| Endpoints and assessments
An electronic diary was issued to all subjects before every EEC session, and was used for assessment of rhinoconjunctivitis symptoms before and during the 6-hour exposure period in the chamber.
The primary efficacy endpoint was the average total symptom score (TSS) measured at 9 time points from hour 2 to 6 during the 6-hour birch EEC session after 24 weeks of treatment.
The average TSS for each subject was calculated as the average sum of the total nasal symptom score consisting of four symptoms (TNSS); runny nose, blocked nose, sneezing, and itchy nose and the total ocular symptom score (TOSS) consisting of two symptoms; gritty feeling/red/itchy eyes and watery eyes. Each of the six symptoms were measured on a scale from 0-3, where 0 corresponds to no symptoms and three corresponds to severe symptoms. Thus, the TSS had a range of 0-18.
At the randomization visit, subjects received an adverse event (AE) notebook to be completed in case the subject experienced any
AEs during the trial. The AE notebook entries served as a basis for AE assessment. At all subsequent visits, the investigator reviewed and discussed data entered in the AE notebook with the subject, and entries fulfilling the requirement for an AE were entered into the eCRF.
| Immunological assessments
At each visit to the trial site, blood samples were collected for immunological assessments. The amount of allergen (Bet v and Que a) specific IgE and IgG 4 antibodies were measured by ImmunoCAP (Phadia 250, Thermo Fischer Scientific, Uppsala, Sweden) and IgE-BF was measured as described previously. 16 The IgE-BF assay is a competition assay supplementing the data for IgG4 and IgE titers with a readout reflecting the combined effect of IgE and non-IgE (IgG 4 ) changes. In addition, it has been shown to correlate to functional assays such as basophil activation test (BAT) and facilitated allergen presentation (FAP) (15).
For immunological cross-reactivity studies, specific serum IgE Table E1 and E2 of the Appendix S1. 
| ImmunoCAP IgE (pretreatment) and IgG 4 (posttreatment) inhibition assays
| Statistical methodology
The efficacy analyses were conducted based on all randomized subjects (full analysis set, FAS) who attended an EEC visit. Statistical tests were two-sided at a 5% significance level unless otherwise specified and confidence intervals were two-sided 95% confidence intervals. All statistical analyses were pre-defined in the statistical analysis plan prior to unblinding.
The primary endpoint (the average TSS during the 24 weeks birch EEC visit) was analyzed using a linear mixed effect (LME) model with the average TSS as the response variable, and treatment, visit, and their two-factor interaction as fixed class effects, the average TSS at baseline EEC as a fixed regression variable, and chamber cohort and subject as random class variables. No adjustments for multiplicity were performed.
The change from baseline of the immunological parameters, Bet v and Que a specific IgE, and IgG 4 , were tested using the post hoc Tukey's HSD method. The log10 transformed values were fitted to a linear repeated measures mixed model using subject ID as a random factor (restricted maximum likelihood). Further details of the statistical methods including sample size calculation and the correlations for antibody response can be found in the Appendix S1.
| RESULTS
| Population
A total of 219 eligible subjects were randomized to blinded treatment with either the SQ tree SLIT-tablet (2, 7, or 12 DU) (N = 163) or placebo (N = 56). During the trial, 19 subjects (9%) discontinued (10 subjects due to AEs) and 200 (91%) subjects completed the trial. By definition, all randomized subjects were included in analyses based on FAS. Subject disposition is summarized in Figure E1 of the Appendix S1. The treatment groups were similar with regard to gender composition (47% female), ethnicity, race, smoking history, age, and BMI. Subject baseline demography is presented in Table E3 in the Appendix S1. In accordance with the inclusion criteria, all subjects were IgE sensitized to birch and had a medical history of birch pollen allergy. The majority of subjects also showed positive skin prick test towards pollen from other members of the birch homology group such as oak (75%) and alder (91%), as well as other perennial and seasonal allergens. 10% of the subjects suffered from asthma.
| Efficacy on rhinoconjunctivitis symptoms
The results of the statistical analyses of the TSS at the 24-weeks birch and oak EEC sessions are presented in Table 1 .
Analysis of the primary endpoint revealed statistically significantly lower TSS during the 24-week birch EEC session for 7 and 12 DU compared to placebo with relative differences of 24% and 25%.
The difference from placebo was numerically higher for 12 DU than for 7 DU although the overall magnitudes of the absolute and relative differences were comparable between the two doses. For the 24-week oak EEC session, a statistically significant difference from placebo was noted for the 12 DU dose (24%, P = 0.03). The results for the secondary endpoints on nasal and ocular symptom scores are shown in Table 2 . Nasal symptoms (ie. TNSS)
were significantly reduced compared to placebo for all three doses at the 24-week birch EEC session. For the 24-week oak EEC session, the TNSS reduction was significant for 12 DU. Eye symptoms TOSS
were not significantly reduced relative to placebo for any dose, although the absolute differences were in favour of treatment.
| Immunological endpoints (IgE, IgG 4 , IgE-BF)
As shown in Figure 3 , the analyses of specific immunological parameters showed that 7 and 12 DU induced statistically significant increases from baseline in serum levels of both birch-and oak-specific IgG 4 compared to placebo whereas 2 DU induced a significant increase only for birch-specific IgG 4 ( Figure 3A and B).
The average birch-and oak-specific IgG 4 titers followed the same trend for all doses and all time points investigated. Similar results were seen for birch-and oak-specific IgE ( Figure 3C and D) and Bet v IgE-BF ( Figure 3E ). Especially for IgE-BF a marked increase could be seen for 7 DU and 12 DU compared to 2 DU and placebo.
| Exploratory immunological analysis
IgE sensitization and the correlation between IgE titers towards individual trees of the birch homologous group is shown in Figure 4 Appendix S1 for details). CI, confidence interval; N, number of subjects attending the EEC session; TNSS, total nasal symptom score; TOSS, total ocular symptom score.
T Figure E2 of the Appendix S1 for details). In the active treatment groups, the three most frequently reported AEs were throat irritation (35%-59% of subjects), tongue pruritus (22%-39% of subjects), and ear pruritus (22%-31% of subjects), and these showed a dose response relationship in terms of number of subjects reporting the AE. SAEs were reported by three subjects (1%) (PTs: tibia fracture (2 DU), glioblastoma (7 DU), and depression (2 DU)); none of these were assessed as related to the IMP. The SQ tree SLIT-tablet was generally well tolerated in all administered doses. The most frequently reported IMP-related AEs were mild or moderate in severity, and most were local reactions related to the sublingual administration of the SQ tree SLIT-tablet, which was expected from prior trials conducted with the grass, ragweed and HDM SLIT-tablets. [19] [20] [21] [22] [23] [24] [25] [26] Generally, tolerability during the trial was similar to observations from prior trials with the SQ tree SLIT- In conclusion, the current trial demonstrates that the SQ tree SLIT-tablet reduce rhinoconjunctivitis symptoms triggered by birch pollen. Results from oak EEC exposure and IgE and IgG 4 measurements suggest that the use of the SQ tree SLIT-tablet may be extended to treatment of ARC induced by all other species within the birch homologous group. The combined evidence from reduction of birch and oak induced rhinoconjunctivitis symptoms during pollen exposure in an EEC suggests that the optimal dose for further development is 12 DU.
| Safety
| DISCUSSION
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